DOTA-Zoledronate | CAS#1908409-18-6 | PET chelator

MedKoo Cat#: 556031 | Name: DOTA-Zoledronate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DOTA-Zoledronate is a bisphosphonates (BP) with macrocyclic chelator, which can bind 177Lu or other radio isotope metals for PET-diagnosis and endoradiotherapy of bone metastases. [177Lu]Lu-DOTAZOL shows maximum absorbed doses in bone and low kidney doses, making it a promising agent for radionuclide therapy of bone metastasis. Further studies are warranted to evaluate the efficacy and safety of radionuclide therapy with [177Lu]Lu-DOTAZOL in the clinical setting.

Chemical Structure

DOTA-Zoledronate

CAS#1908409-18-6 (free)

Theoretical Analysis

MedKoo Cat#: 556031

Name: DOTA-Zoledronate

CAS#: 1908409-18-6 (free)

Chemical Formula: C23H41N7O14P2

Exact Mass: 701.2187

Molecular Weight: 701.56

Elemental Analysis: C, 39.38; H, 5.89; N, 13.98; O, 31.93; P, 8.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

DOTA-Zoledronate HCl 1908409-18-6 (free)

Synonym

DOTA-Zoledronate; DOTA-Zoledronate conjugate, DOTA-Zoledranate; DOTA-Zol;

IUPAC/Chemical Name

2,2',2''-(10-(2-((2-(1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid

InChi Key

BRTYHOUKEJCOEE-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H41N7O14P2/c31-19(24-2-1-18-11-30(17-25-18)16-23(38,45(39,40)41)46(42,43)44)12-26-3-5-27(13-20(32)33)7-9-29(15-22(36)37)10-8-28(6-4-26)14-21(34)35/h11,17,38H,1-10,12-16H2,(H,24,31)(H,32,33)(H,34,35)(H,36,37)(H2,39,40,41)(H2,42,43,44)

SMILES Code

O=C(NCCC1=CN(CC(P(O)(O)=O)(O)P(O)(O)=O)C=N1)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 701.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Fernández R, Eppard E, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Ceballos M, Ribbeck J, Kluge A, Rösch F, Meckel M, Zhernosekov K, Kramer V, Amaral H. Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases. J Nucl Med. 2021 Aug 1;62(8):1126-1132. doi: 10.2967/jnumed.120.255851. Epub 2021 Jan 8. PMID: 33419945. 2: Meisenheimer M, Kürpig S, Essler M, Eppard E. DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine. Molecules. 2020 Jun 30;25(13):2988. doi: 10.3390/molecules25132988. PMID: 32629930; PMCID: PMC7412164. 3: Kreppel B, Gaertner FC, Ahmadzadehfar H, Khawar A, Roesch F, Kürpig S, Meisenheimer M, Essler M, Bundschuh RA. [177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinoma. Nuklearmedizin. 2020 Jun;59(3):281-283. doi: 10.1055/a-1151-4592. Epub 2020 Apr 28. PMID: 32344437. 4: Khawar A, Eppard E, Roesch F, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Gaertner FC, Essler M, Bundschuh RA. Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results. EJNMMI Res. 2019 Nov 28;9(1):102. doi: 10.1186/s13550-019-0566-x. PMID: 31781962; PMCID: PMC6882969. 5: Khawar A, Eppard E, Roesch F, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Gaertner FC, Essler M, Bundschuh RA. Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases. Ann Nucl Med. 2019 Jun;33(6):404-413. doi: 10.1007/s12149-019-01348-7. Epub 2019 Mar 15. PMID: 30877560. 6: Pfannkuchen N, Bausbacher N, Pektor S, Miederer M, Rosch F. In vivo Evaluation of [225Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases. Curr Radiopharm. 2018;11(3):223-230. doi: 10.2174/1874471011666180604083911. PMID: 29866026. 7: Meckel M, Bergmann R, Miederer M, Roesch F. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid. EJNMMI Radiopharm Chem. 2017;1(1):14. doi: 10.1186/s41181-016-0017-1. Epub 2016 Sep 23. Erratum in: EJNMMI Radiopharm Chem. 2018 Nov 26;3:13. PMID: 29564390; PMCID: PMC5843815. 8: Chopra A. 68Ga-Labeled (4-{[(bis(phosphonomethyl))carbamoyl]methyl }-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid (BPAMD). 2012 Sep 18 [updated 2012 Nov 21]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 23193622.